









Markets
/
Stocks
/
nasdaq-axgn
/

AxoGen Inc

AXGN

35.583USD

+0.563+1.61%

Market hours （ET）Quotes delayed by 15 min

1.64BMarket Cap

LossP/E TTM



AxoGen Inc

35.583

+0.563+1.61%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AxoGen Inc

Currency: USD Updated: 2026-02-02

Key Insights

AxoGen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.60.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AxoGen Inc's Score

Industry at a Glance

Industry Ranking

3 / 206

Overall Ranking

44 / 4529

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

AxoGen Inc Highlights

StrengthsRisks

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.18% year-on-year.

Undervalued

The company’s latest PE is -837.40, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 42.08M shares, increasing 0.02% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.15K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.01.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

36.600

Target Price

+5.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-02

The current financial score of AxoGen Inc is 8.53, ranking 38 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 60.08M, representing a year-over-year increase of 23.51%, while its net profit experienced a year-over-year increase of 138.11%.

Score

Industry at a Glance

Previous score

8.53

Change



Financials

7.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.55

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.90

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.38

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

AxoGen Inc's Company Valuation

Currency: USD Updated: 2026-02-02

The current valuation score of AxoGen Inc is 7.42, ranking 90 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -837.40, which is -99.21% below the recent high of -6.64 and 0.00% above the recent low of -837.40.

Score

Industry at a Glance

Previous score

7.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-02

The current earnings forecast score of AxoGen Inc is 8.40, ranking 32 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 36.00, with a high of 40.00 and a low of 27.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

36.600

Target Price

+5.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

AxoGen Inc

AXGN

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-02

The current price momentum score of AxoGen Inc is 9.51, ranking 3 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 37.36 and the support level at 31.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.61

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.309

Buy

RSI(14)

64.057

Neutral

STOCH(KDJ)(9,3,3)

79.159

Neutral

ATR(14)

1.451

High Vlolatility

CCI(14)

115.669

Buy

Williams %R

16.197

Overbought

TRIX(12,20)

0.355

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

34.514

Buy

MA10

33.700

Buy

MA20

32.758

Buy

MA50

31.290

Buy

MA100

25.152

Buy

MA200

19.097

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-02

The current institutional shareholding score of AxoGen Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 97.83%, representing a quarter-over-quarter decrease of 3.81%. The largest institutional shareholder is The Vanguard, holding a total of 2.86M shares, representing 5.70% of shares outstanding, with 2.68% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

First Light Asset Management, LLC

5.81M

+28.18%

BlackRock Institutional Trust Company, N.A.

3.18M

+2.47%

The Vanguard Group, Inc.

Star Investors

2.67M

-1.87%

Morgan Stanley & Co. LLC

2.29M

+18.22%

ArrowMark Colorado Holdings, LLC

1.96M

+20.45%

Soleus Capital Management, L.P.

1.73M

+18.31%

Wasatch Global Investors Inc

Star Investors

1.64M

+14.34%

Assenagon Asset Management S.A.

1.29M

+25.99%

Balyasny Asset Management LP

1.38M

-28.56%

Armistice Capital LLC

1.20M

+7.98%

Risk Assessment

Currency: USD Updated: 2026-02-02

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AxoGen Inc is 5.93, ranking 70 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.